中枢神経系経口薬のグローバル市場予測2023-2029

◆英語タイトル:Global CNS Oral Drugs Market Growth 2023-2029

LP Informationが発行した調査報告書(LP23OT9016)◆商品コード:LP23OT9016
◆発行会社(リサーチ会社):LP Information
◆発行日:2023年10月
◆ページ数:115
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品&ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥549,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥823,500見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,098,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「中枢神経系経口薬のグローバル市場」は、過去の販売実績から2022年の世界の中枢神経系経口薬の総販売量を検討し、2023年から2029年の予測される中枢神経系経口薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の中枢神経系経口薬の市場規模を掲載し、XXX百万米ドル規模の世界の中枢神経系経口薬市場の詳細な分析を提供します。本インサイトレポートは、世界の中枢神経系経口薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の中枢神経系経口薬市場における各社の独自のポジションをより深く理解するために、中枢神経系経口薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の中枢神経系経口薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。中枢神経系経口薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000%と予測されています。中枢神経系経口薬の中国市場は、2023年から2029年までの年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。中枢神経系経口薬のヨーロッパ市場は、2023年から2029年にかけて年平均000%成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

中枢神経系経口薬の世界主要メーカーとしては、Pfizer、 Biogen、 Otsuka、 Novartis、 Teva Pharmaceutical、 Johnson & Johnson、 AstraZeneca、 Merck、 GSK、 Eli Lilly and Company、 Lundbeck、 Takeda、 Bristol Myers Squibb、 Jiangsu Nhwa Pharmaceutical、 Luye Pharma、 Zhejiang Huahai Pharmaceutical、 Chengdu Easton Biopharmaceuticals、 Hansoh Pharmaceuticalなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000%のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の中枢神経系経口薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では中枢神経系経口薬市場をセグメンテーションし、種類別 (抗うつ薬、抗精神病薬、抗認知症薬、抗パーキンソン病薬、抗てんかん薬、その他)、用途別 (病院・クリニック、薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分:抗うつ薬、抗精神病薬、抗認知症薬、抗パーキンソン病薬、抗てんかん薬、その他

・用途別区分:病院・クリニック、薬局

・地域別区分
南北アメリカ(米国、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東・アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

【本レポートで扱う主な質問】

・世界の中枢神経系経口薬市場の10年間の市場状況・展望は?
・世界および地域別に見た中枢神経系経口薬市場成長の要因は何か?
・中枢神経系経口薬の市場機会はエンドマーケットの規模によってどのように変化するのか?
・中枢神経系経口薬のタイプ別、用途別の内訳は?
・新型コロナウイルスとロシア・ウクライナ戦争の影響は?

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:中枢神経系経口薬の年間販売量2018-2029、地域別現状・将来分析
・中枢神経系経口薬の種類別セグメント:抗うつ薬、抗精神病薬、抗認知症薬、抗パーキンソン病薬、抗てんかん薬、その他
・中枢神経系経口薬の種類別販売量:2018-2023年の販売量、売上、市場シェア、販売価格
・中枢神経系経口薬の用途別セグメント:病院・クリニック、薬局
・中枢神経系経口薬の用途別販売量:2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の中枢神経系経口薬市場
・企業別のグローバル中枢神経系経口薬市場データ:2018-2023年の年間販売量、市場シェア
・企業別の中枢神経系経口薬の年間売上:2018-2023年の売上、市場シェア
・企業別の中枢神経系経口薬販売価格
・主要企業の中枢神経系経口薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

中枢神経系経口薬の地域別レビュー
・地域別の中枢神経系経口薬市場規模2018-2023:年間販売量、売上
・主要国別の中枢神経系経口薬市場規模2018-2023:年間販売量、売上
・南北アメリカの中枢神経系経口薬販売の成長
・アジア太平洋の中枢神経系経口薬販売の成長
・ヨーロッパの中枢神経系経口薬販売の成長
・中東・アフリカの中枢神経系経口薬販売の成長

南北アメリカ市場
・南北アメリカの国別の中枢神経系経口薬販売量、売上(2018-2023)
・南北アメリカの中枢神経系経口薬の種類別販売量
・南北アメリカの中枢神経系経口薬の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の中枢神経系経口薬販売量、売上(2018-2023)
・アジア太平洋の中枢神経系経口薬の種類別販売量
・アジア太平洋の中枢神経系経口薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の中枢神経系経口薬販売量、売上(2018-2023)
・ヨーロッパの中枢神経系経口薬の種類別販売量
・ヨーロッパの中枢神経系経口薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の中枢神経系経口薬販売量、売上(2018-2023)
・中東・アフリカの中枢神経系経口薬の種類別販売量
・中東・アフリカの中枢神経系経口薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・中枢神経系経口薬の製造コスト構造分析
・中枢神経系経口薬の製造プロセス分析
・中枢神経系経口薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・中枢神経系経口薬の主要なグローバル販売業者
・中枢神経系経口薬の主要なグローバル顧客

地域別の中枢神経系経口薬市場予測レビュー
・地域別の中枢神経系経口薬市場規模予測(2024-2029)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・中枢神経系経口薬の種類別市場規模予測
・中枢神経系経口薬の用途別市場規模予測

主要企業分析
Pfizer、 Biogen、 Otsuka、 Novartis、 Teva Pharmaceutical、 Johnson & Johnson、 AstraZeneca、 Merck、 GSK、 Eli Lilly and Company、 Lundbeck、 Takeda、 Bristol Myers Squibb、 Jiangsu Nhwa Pharmaceutical、 Luye Pharma、 Zhejiang Huahai Pharmaceutical、 Chengdu Easton Biopharmaceuticals、 Hansoh Pharmaceutical
・企業情報
・中枢神経系経口薬製品
・中枢神経系経口薬販売量、売上、価格、粗利益(2018-2023)
・主要ビジネス概要
・最新動向

調査結果および結論

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CNS Oral Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for CNS Oral Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for CNS Oral Drugs by Country/Region, 2018, 2022 & 2029
2.2 CNS Oral Drugs Segment by Type
2.2.1 Antidepressants
2.2.2 Antipsychotics
2.2.3 Anti-Dementia Drugs
2.2.4 Anti-Parkinson’s Drugs
2.2.5 Antiepileptic Drugs
2.2.6 Others
2.3 CNS Oral Drugs Sales by Type
2.3.1 Global CNS Oral Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global CNS Oral Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global CNS Oral Drugs Sale Price by Type (2018-2023)
2.4 CNS Oral Drugs Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Pharmacy
2.5 CNS Oral Drugs Sales by Application
2.5.1 Global CNS Oral Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global CNS Oral Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global CNS Oral Drugs Sale Price by Application (2018-2023)
3 Global CNS Oral Drugs by Company
3.1 Global CNS Oral Drugs Breakdown Data by Company
3.1.1 Global CNS Oral Drugs Annual Sales by Company (2018-2023)
3.1.2 Global CNS Oral Drugs Sales Market Share by Company (2018-2023)
3.2 Global CNS Oral Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global CNS Oral Drugs Revenue by Company (2018-2023)
3.2.2 Global CNS Oral Drugs Revenue Market Share by Company (2018-2023)
3.3 Global CNS Oral Drugs Sale Price by Company
3.4 Key Manufacturers CNS Oral Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CNS Oral Drugs Product Location Distribution
3.4.2 Players CNS Oral Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CNS Oral Drugs by Geographic Region
4.1 World Historic CNS Oral Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global CNS Oral Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global CNS Oral Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic CNS Oral Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global CNS Oral Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global CNS Oral Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas CNS Oral Drugs Sales Growth
4.4 APAC CNS Oral Drugs Sales Growth
4.5 Europe CNS Oral Drugs Sales Growth
4.6 Middle East & Africa CNS Oral Drugs Sales Growth
5 Americas
5.1 Americas CNS Oral Drugs Sales by Country
5.1.1 Americas CNS Oral Drugs Sales by Country (2018-2023)
5.1.2 Americas CNS Oral Drugs Revenue by Country (2018-2023)
5.2 Americas CNS Oral Drugs Sales by Type
5.3 Americas CNS Oral Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CNS Oral Drugs Sales by Region
6.1.1 APAC CNS Oral Drugs Sales by Region (2018-2023)
6.1.2 APAC CNS Oral Drugs Revenue by Region (2018-2023)
6.2 APAC CNS Oral Drugs Sales by Type
6.3 APAC CNS Oral Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CNS Oral Drugs by Country
7.1.1 Europe CNS Oral Drugs Sales by Country (2018-2023)
7.1.2 Europe CNS Oral Drugs Revenue by Country (2018-2023)
7.2 Europe CNS Oral Drugs Sales by Type
7.3 Europe CNS Oral Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CNS Oral Drugs by Country
8.1.1 Middle East & Africa CNS Oral Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa CNS Oral Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa CNS Oral Drugs Sales by Type
8.3 Middle East & Africa CNS Oral Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CNS Oral Drugs
10.3 Manufacturing Process Analysis of CNS Oral Drugs
10.4 Industry Chain Structure of CNS Oral Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CNS Oral Drugs Distributors
11.3 CNS Oral Drugs Customer
12 World Forecast Review for CNS Oral Drugs by Geographic Region
12.1 Global CNS Oral Drugs Market Size Forecast by Region
12.1.1 Global CNS Oral Drugs Forecast by Region (2024-2029)
12.1.2 Global CNS Oral Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CNS Oral Drugs Forecast by Type
12.7 Global CNS Oral Drugs Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer CNS Oral Drugs Product Portfolios and Specifications
13.1.3 Pfizer CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen CNS Oral Drugs Product Portfolios and Specifications
13.2.3 Biogen CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Otsuka
13.3.1 Otsuka Company Information
13.3.2 Otsuka CNS Oral Drugs Product Portfolios and Specifications
13.3.3 Otsuka CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Otsuka Main Business Overview
13.3.5 Otsuka Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis CNS Oral Drugs Product Portfolios and Specifications
13.4.3 Novartis CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Teva Pharmaceutical
13.5.1 Teva Pharmaceutical Company Information
13.5.2 Teva Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.5.3 Teva Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Teva Pharmaceutical Main Business Overview
13.5.5 Teva Pharmaceutical Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson CNS Oral Drugs Product Portfolios and Specifications
13.6.3 Johnson & Johnson CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 AstraZeneca
13.7.1 AstraZeneca Company Information
13.7.2 AstraZeneca CNS Oral Drugs Product Portfolios and Specifications
13.7.3 AstraZeneca CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 AstraZeneca Main Business Overview
13.7.5 AstraZeneca Latest Developments
13.8 Merck
13.8.1 Merck Company Information
13.8.2 Merck CNS Oral Drugs Product Portfolios and Specifications
13.8.3 Merck CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck Main Business Overview
13.8.5 Merck Latest Developments
13.9 GSK
13.9.1 GSK Company Information
13.9.2 GSK CNS Oral Drugs Product Portfolios and Specifications
13.9.3 GSK CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 GSK Main Business Overview
13.9.5 GSK Latest Developments
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Information
13.10.2 Eli Lilly and Company CNS Oral Drugs Product Portfolios and Specifications
13.10.3 Eli Lilly and Company CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly and Company Main Business Overview
13.10.5 Eli Lilly and Company Latest Developments
13.11 Lundbeck
13.11.1 Lundbeck Company Information
13.11.2 Lundbeck CNS Oral Drugs Product Portfolios and Specifications
13.11.3 Lundbeck CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Lundbeck Main Business Overview
13.11.5 Lundbeck Latest Developments
13.12 Takeda
13.12.1 Takeda Company Information
13.12.2 Takeda CNS Oral Drugs Product Portfolios and Specifications
13.12.3 Takeda CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Takeda Main Business Overview
13.12.5 Takeda Latest Developments
13.13 Bristol Myers Squibb
13.13.1 Bristol Myers Squibb Company Information
13.13.2 Bristol Myers Squibb CNS Oral Drugs Product Portfolios and Specifications
13.13.3 Bristol Myers Squibb CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Bristol Myers Squibb Main Business Overview
13.13.5 Bristol Myers Squibb Latest Developments
13.14 Jiangsu Nhwa Pharmaceutical
13.14.1 Jiangsu Nhwa Pharmaceutical Company Information
13.14.2 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.14.3 Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Jiangsu Nhwa Pharmaceutical Main Business Overview
13.14.5 Jiangsu Nhwa Pharmaceutical Latest Developments
13.15 Luye Pharma
13.15.1 Luye Pharma Company Information
13.15.2 Luye Pharma CNS Oral Drugs Product Portfolios and Specifications
13.15.3 Luye Pharma CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Luye Pharma Main Business Overview
13.15.5 Luye Pharma Latest Developments
13.16 Zhejiang Huahai Pharmaceutical
13.16.1 Zhejiang Huahai Pharmaceutical Company Information
13.16.2 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.16.3 Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Zhejiang Huahai Pharmaceutical Main Business Overview
13.16.5 Zhejiang Huahai Pharmaceutical Latest Developments
13.17 Chengdu Easton Biopharmaceuticals
13.17.1 Chengdu Easton Biopharmaceuticals Company Information
13.17.2 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product Portfolios and Specifications
13.17.3 Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Chengdu Easton Biopharmaceuticals Main Business Overview
13.17.5 Chengdu Easton Biopharmaceuticals Latest Developments
13.18 Hansoh Pharmaceutical
13.18.1 Hansoh Pharmaceutical Company Information
13.18.2 Hansoh Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
13.18.3 Hansoh Pharmaceutical CNS Oral Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Hansoh Pharmaceutical Main Business Overview
13.18.5 Hansoh Pharmaceutical Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. CNS Oral Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. CNS Oral Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Antidepressants
Table 4. Major Players of Antipsychotics
Table 5. Major Players of Anti-Dementia Drugs
Table 6. Major Players of Anti-Parkinson's Drugs
Table 7. Major Players of Antiepileptic Drugs
Table 8. Major Players of Others
Table 9. Global CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global CNS Oral Drugs Sales Market Share by Type (2018-2023)
Table 11. Global CNS Oral Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global CNS Oral Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global CNS Oral Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global CNS Oral Drugs Sales Market Share by Application (2018-2023)
Table 16. Global CNS Oral Drugs Revenue by Application (2018-2023)
Table 17. Global CNS Oral Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global CNS Oral Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global CNS Oral Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global CNS Oral Drugs Sales Market Share by Company (2018-2023)
Table 21. Global CNS Oral Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global CNS Oral Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global CNS Oral Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers CNS Oral Drugs Producing Area Distribution and Sales Area
Table 25. Players CNS Oral Drugs Products Offered
Table 26. CNS Oral Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global CNS Oral Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global CNS Oral Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global CNS Oral Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global CNS Oral Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global CNS Oral Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global CNS Oral Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global CNS Oral Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global CNS Oral Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC CNS Oral Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC CNS Oral Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC CNS Oral Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC CNS Oral Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa CNS Oral Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa CNS Oral Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa CNS Oral Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa CNS Oral Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa CNS Oral Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa CNS Oral Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of CNS Oral Drugs
Table 62. Key Market Challenges & Risks of CNS Oral Drugs
Table 63. Key Industry Trends of CNS Oral Drugs
Table 64. CNS Oral Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. CNS Oral Drugs Distributors List
Table 67. CNS Oral Drugs Customer List
Table 68. Global CNS Oral Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global CNS Oral Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC CNS Oral Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC CNS Oral Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa CNS Oral Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa CNS Oral Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global CNS Oral Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global CNS Oral Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global CNS Oral Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global CNS Oral Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Pfizer Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer CNS Oral Drugs Product Portfolios and Specifications
Table 84. Pfizer CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. Biogen Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Biogen CNS Oral Drugs Product Portfolios and Specifications
Table 89. Biogen CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Biogen Main Business
Table 91. Biogen Latest Developments
Table 92. Otsuka Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Otsuka CNS Oral Drugs Product Portfolios and Specifications
Table 94. Otsuka CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Otsuka Main Business
Table 96. Otsuka Latest Developments
Table 97. Novartis Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis CNS Oral Drugs Product Portfolios and Specifications
Table 99. Novartis CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Teva Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Teva Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 104. Teva Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Teva Pharmaceutical Main Business
Table 106. Teva Pharmaceutical Latest Developments
Table 107. Johnson & Johnson Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Johnson & Johnson CNS Oral Drugs Product Portfolios and Specifications
Table 109. Johnson & Johnson CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Johnson & Johnson Main Business
Table 111. Johnson & Johnson Latest Developments
Table 112. AstraZeneca Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. AstraZeneca CNS Oral Drugs Product Portfolios and Specifications
Table 114. AstraZeneca CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. AstraZeneca Main Business
Table 116. AstraZeneca Latest Developments
Table 117. Merck Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Merck CNS Oral Drugs Product Portfolios and Specifications
Table 119. Merck CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Merck Main Business
Table 121. Merck Latest Developments
Table 122. GSK Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. GSK CNS Oral Drugs Product Portfolios and Specifications
Table 124. GSK CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. GSK Main Business
Table 126. GSK Latest Developments
Table 127. Eli Lilly and Company Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Eli Lilly and Company CNS Oral Drugs Product Portfolios and Specifications
Table 129. Eli Lilly and Company CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Eli Lilly and Company Main Business
Table 131. Eli Lilly and Company Latest Developments
Table 132. Lundbeck Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Lundbeck CNS Oral Drugs Product Portfolios and Specifications
Table 134. Lundbeck CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Lundbeck Main Business
Table 136. Lundbeck Latest Developments
Table 137. Takeda Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Takeda CNS Oral Drugs Product Portfolios and Specifications
Table 139. Takeda CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Takeda Main Business
Table 141. Takeda Latest Developments
Table 142. Bristol Myers Squibb Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 143. Bristol Myers Squibb CNS Oral Drugs Product Portfolios and Specifications
Table 144. Bristol Myers Squibb CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Bristol Myers Squibb Main Business
Table 146. Bristol Myers Squibb Latest Developments
Table 147. Jiangsu Nhwa Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 148. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 149. Jiangsu Nhwa Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Jiangsu Nhwa Pharmaceutical Main Business
Table 151. Jiangsu Nhwa Pharmaceutical Latest Developments
Table 152. Luye Pharma Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 153. Luye Pharma CNS Oral Drugs Product Portfolios and Specifications
Table 154. Luye Pharma CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Luye Pharma Main Business
Table 156. Luye Pharma Latest Developments
Table 157. Zhejiang Huahai Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 158. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 159. Zhejiang Huahai Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 160. Zhejiang Huahai Pharmaceutical Main Business
Table 161. Zhejiang Huahai Pharmaceutical Latest Developments
Table 162. Chengdu Easton Biopharmaceuticals Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 163. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Product Portfolios and Specifications
Table 164. Chengdu Easton Biopharmaceuticals CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 165. Chengdu Easton Biopharmaceuticals Main Business
Table 166. Chengdu Easton Biopharmaceuticals Latest Developments
Table 167. Hansoh Pharmaceutical Basic Information, CNS Oral Drugs Manufacturing Base, Sales Area and Its Competitors
Table 168. Hansoh Pharmaceutical CNS Oral Drugs Product Portfolios and Specifications
Table 169. Hansoh Pharmaceutical CNS Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 170. Hansoh Pharmaceutical Main Business
Table 171. Hansoh Pharmaceutical Latest Developments
List of Figures
Figure 1. Picture of CNS Oral Drugs
Figure 2. CNS Oral Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CNS Oral Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global CNS Oral Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. CNS Oral Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Antidepressants
Figure 10. Product Picture of Antipsychotics
Figure 11. Product Picture of Anti-Dementia Drugs
Figure 12. Product Picture of Anti-Parkinson's Drugs
Figure 13. Product Picture of Antiepileptic Drugs
Figure 14. Product Picture of Others
Figure 15. Global CNS Oral Drugs Sales Market Share by Type in 2022
Figure 16. Global CNS Oral Drugs Revenue Market Share by Type (2018-2023)
Figure 17. CNS Oral Drugs Consumed in Hospital and Clinic
Figure 18. Global CNS Oral Drugs Market: Hospital and Clinic (2018-2023) & (K Units)
Figure 19. CNS Oral Drugs Consumed in Pharmacy
Figure 20. Global CNS Oral Drugs Market: Pharmacy (2018-2023) & (K Units)
Figure 21. Global CNS Oral Drugs Sales Market Share by Application (2022)
Figure 22. Global CNS Oral Drugs Revenue Market Share by Application in 2022
Figure 23. CNS Oral Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global CNS Oral Drugs Sales Market Share by Company in 2022
Figure 25. CNS Oral Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global CNS Oral Drugs Revenue Market Share by Company in 2022
Figure 27. Global CNS Oral Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global CNS Oral Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 30. Americas CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 32. APAC CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 34. Europe CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa CNS Oral Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa CNS Oral Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas CNS Oral Drugs Sales Market Share by Country in 2022
Figure 38. Americas CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 39. Americas CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC CNS Oral Drugs Sales Market Share by Region in 2022
Figure 46. APAC CNS Oral Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 49. China CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe CNS Oral Drugs Sales Market Share by Country in 2022
Figure 57. Europe CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 58. Europe CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa CNS Oral Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa CNS Oral Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa CNS Oral Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa CNS Oral Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country CNS Oral Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of CNS Oral Drugs in 2022
Figure 75. Manufacturing Process Analysis of CNS Oral Drugs
Figure 76. Industry Chain Structure of CNS Oral Drugs
Figure 77. Channels of Distribution
Figure 78. Global CNS Oral Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global CNS Oral Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global CNS Oral Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global CNS Oral Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global CNS Oral Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global CNS Oral Drugs Revenue Market Share Forecast by Application (2024-2029)


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 中枢神経系経口薬のグローバル市場予測2023-2029(Global CNS Oral Drugs Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆